MEDP supply chain intelligence for Medpace Holdings, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Medpace Holdings, Inc. (MEDP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CBIH | Cannabis Bioscience International Holdings, Inc. | 72% | Reciprocal relationship from CBIH graph: Reciprocal relationship from MEDP graph: Reciprocal relationship from CBIH graph: Reciprocal relationship from MEDP graph: Reciprocal relationship from CBIH g… |
| IQV | IQVIA Holdings Inc. | 72% | d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, the management of sales force effectiveness and the creation of a process whereby… |
| IQV | IQVIA Holdings Inc. | 72% | Reciprocal relationship from IQV graph: Reciprocal relationship from MEDP graph: Reciprocal relationship from IQV graph: Reciprocal relationship from MEDP graph: d and disciplined approach facilitate… |
| TMO | Thermo Fisher Scientific Inc. | 72% | d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, the management of sales force effectiveness and the creation of a process whereby… |
| TMO | Thermo Fisher Scientific Inc. | 72% | Reciprocal relationship from TMO graph: Reciprocal relationship from MEDP graph: d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CINRX-PHARMA | CINRX-PHARMA | 92% | The Company recognized total revenue from CinRx of $ 6.1 million and $ 11.7 million during the three months ended March 31, 2026 and 2025, respectively, in the Company’s condensed consolidated statem… |
| LIB-THERAPEUTICS-LLC | LIB-THERAPEUTICS-LLC | 92% | The Company recognized total revenue from LIB of $ 1.2 million and $ 2.2 million during the three months ended March 31, 2026 and 2025, respectively, in the Company’s condensed consolidated statement… |
| CLINTRAK | CLINTRAK | 90% | We already provide access to such an information system, ClinTrak, to certain of our customers in connection with the services we provide to them. |
| IQV | IQVIA Holdings Inc. | 72% | Reciprocal relationship from IQV graph: Reciprocal relationship from MEDP graph: d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, … |
| IQV | IQVIA Holdings Inc. | 72% | d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, the management of sales force effectiveness and the creation of a process whereby… |
| TMO | Thermo Fisher Scientific Inc. | 72% | d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, the management of sales force effectiveness and the creation of a process whereby… |
| TMO | Thermo Fisher Scientific Inc. | 72% | Reciprocal relationship from TMO graph: Reciprocal relationship from MEDP graph: d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, … |
| AIRCRAFT-MANAGEMENT-COMPANY | AIRCRAFT-MANAGEMENT-COMPANY | 62% | any to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2… |
| MEDPACE-INTERMEDIATECO-INC | MEDPACE-INTERMEDIATECO-INC | 62% | unbilled, net consisted of the following (in thousands): As of March 31, 2026 December 31, 2025 Accounts receivable $ 370,407 $ 376,755 Unbilled receivables 24,202 25,352 Less: allowance for doubtful… |
| SERVICE-AGREEMENT-LIB-THERAPEUTICS-LLC | SERVICE-AGREEMENT-LIB-THERAPEUTICS-LLC | 62% | l pricing. The commitments expire at various times through 2030. (12) Related Party Transactions Employee Loans The Company periodically extends short term loans or advances to employees, typically u… |
| SERVICE-AGREEMENTS-LIB-THERAPEUTICS-LLC | SERVICE-AGREEMENTS-LIB-THERAPEUTICS-LLC | 62% | laneous income (expense), net $ 4,056 $ ( 655 ) $ 7,068 14. RELATED PARTY TRANSACTIONS Employee Loans The Company periodically extends short term loans or advances to employees, typically upon commen… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MEDP-DEBT | Debt stack $146.1M | 90% | Market cache reports total debt of $146.1M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MEDP-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 731 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| IQV | IQVIA Holdings Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| TMO | Thermo Fisher Scientific Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 50.00 | 2 | ['supplier'] |
| FTRE | Fortrea Holdings Inc. | 50.00 | 2 | |
| SUPN | Supernus Pharmaceuticals, Inc. | 50.00 | 2 | |
| RGEN | Repligen Corporation | 50.00 | 2 | |
| BHPLF | BHP Group Limited | 50.00 | 2 | |
| CLLS | Cellectis S.A. | 50.00 | 2 | |
| ICLR | ICON Public Limited Company | 50.00 | 2 | |
| DNA | Ginkgo Bioworks Holdings, Inc. | 50.00 | 2 | |
| IDXG | Interpace Biosciences, Inc. | 50.00 | 2 | |
| GH | Guardant Health, Inc. | 50.00 | 2 | |
| IMTX | Immatics N.V. | 50.00 | 2 | |
| SVRA | Savara Inc. | 50.00 | 2 | |
| TECH | Bio-Techne Corporation | 50.00 | 2 | |
| TEM | Tempus AI, Inc. | 50.00 | 2 | |
| HRMY | Harmony Biosciences Holdings, Inc. | 50.00 | 2 | |
| HUMA | Humacyte, Inc. | 50.00 | 2 | |
| AZTA | Azenta, Inc. | 50.00 | 2 | |
| TWST | Twist Bioscience Corporation | 50.00 | 2 |